Avapritinib: a new tyrosine kinase inhibitor for treatment of advanced gastrointestinal stromal tumors. The literature review and clinical case

We have three drugs for treatment of gastrointestinal stromal tumors (GIST): imatinib, sunitinib and regorafenib. Avapritinib (Ayvakit, BLU-285) is one more drug that was approved in January 2020. Avapritinib is a new selective tyrosine kinase inhibitor of PDGFRA and KIT mutations. Based on NAVIGATO...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Daria A. Filonenko, Bela M. Medvedeva, Andrey A. Meshcheryakov
Formato:	article
Lenguaje:	RU
Publicado:	IP Habib O.N. 2021
Materias:	gastrointestinal stromal tumors pdgfra avapritinib blu-285 ayvakit Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/6e46ed6345224af8a1b117b56a28b0d7
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:6e46ed6345224af8a1b117b56a28b0d7
record_format	dspace
spelling	oai:doaj.org-article:6e46ed6345224af8a1b117b56a28b0d72021-11-30T17:03:34ZAvapritinib: a new tyrosine kinase inhibitor for treatment of advanced gastrointestinal stromal tumors. The literature review and clinical case1815-14341815-144210.26442/18151434.2020.4.200409https://doaj.org/article/6e46ed6345224af8a1b117b56a28b0d72021-02-01T00:00:00Zhttps://modernonco.orscience.ru/1815-1434/article/viewFile/61163/44252https://doaj.org/toc/1815-1434https://doaj.org/toc/1815-1442We have three drugs for treatment of gastrointestinal stromal tumors (GIST): imatinib, sunitinib and regorafenib. Avapritinib (Ayvakit, BLU-285) is one more drug that was approved in January 2020. Avapritinib is a new selective tyrosine kinase inhibitor of PDGFRA and KIT mutations. Based on NAVIGATOR trial avapritinib was approved by FDA for treatment of PDGFRA exon 18 mutant GIST including D842V. Avapritinib was included in NCCN guidelines in the first line therapy PDGFRA D842V mutant GIST. There are only several cases describe imatinib and regorafenib efficacy in D842V mutation in the literature. Avapritinib is the first drug with high efficacy in D842V mutant GIST. Avapritinib has high efficacy against second mutations that explain its activity in 4 lines of treatment. This article summarizes the results of NAVIGATOR trial and describes a clinical case of the patient with advanced GIST who received avapritinib in 6th line of treatment. Partial response was achieved that lasted 9 months. The earliest side effects were periorbital edema and increased lacrimation. Three months later the dose of аvapritinib was reduced because of hematological toxicity.Daria A. FilonenkoBela M. MedvedevaAndrey A. MeshcheryakovIP Habib O.N.articlegastrointestinal stromal tumorspdgfraavapritinibblu-285ayvakitNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282RUСовременная онкология, Vol 22, Iss 4, Pp 96-100 (2021)
institution	DOAJ
collection	DOAJ
language	RU
topic	gastrointestinal stromal tumors pdgfra avapritinib blu-285 ayvakit Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	gastrointestinal stromal tumors pdgfra avapritinib blu-285 ayvakit Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Daria A. Filonenko Bela M. Medvedeva Andrey A. Meshcheryakov Avapritinib: a new tyrosine kinase inhibitor for treatment of advanced gastrointestinal stromal tumors. The literature review and clinical case
description	We have three drugs for treatment of gastrointestinal stromal tumors (GIST): imatinib, sunitinib and regorafenib. Avapritinib (Ayvakit, BLU-285) is one more drug that was approved in January 2020. Avapritinib is a new selective tyrosine kinase inhibitor of PDGFRA and KIT mutations. Based on NAVIGATOR trial avapritinib was approved by FDA for treatment of PDGFRA exon 18 mutant GIST including D842V. Avapritinib was included in NCCN guidelines in the first line therapy PDGFRA D842V mutant GIST. There are only several cases describe imatinib and regorafenib efficacy in D842V mutation in the literature. Avapritinib is the first drug with high efficacy in D842V mutant GIST. Avapritinib has high efficacy against second mutations that explain its activity in 4 lines of treatment. This article summarizes the results of NAVIGATOR trial and describes a clinical case of the patient with advanced GIST who received avapritinib in 6th line of treatment. Partial response was achieved that lasted 9 months. The earliest side effects were periorbital edema and increased lacrimation. Three months later the dose of аvapritinib was reduced because of hematological toxicity.
format	article
author	Daria A. Filonenko Bela M. Medvedeva Andrey A. Meshcheryakov
author_facet	Daria A. Filonenko Bela M. Medvedeva Andrey A. Meshcheryakov
author_sort	Daria A. Filonenko
title	Avapritinib: a new tyrosine kinase inhibitor for treatment of advanced gastrointestinal stromal tumors. The literature review and clinical case
title_short	Avapritinib: a new tyrosine kinase inhibitor for treatment of advanced gastrointestinal stromal tumors. The literature review and clinical case
title_full	Avapritinib: a new tyrosine kinase inhibitor for treatment of advanced gastrointestinal stromal tumors. The literature review and clinical case
title_fullStr	Avapritinib: a new tyrosine kinase inhibitor for treatment of advanced gastrointestinal stromal tumors. The literature review and clinical case
title_full_unstemmed	Avapritinib: a new tyrosine kinase inhibitor for treatment of advanced gastrointestinal stromal tumors. The literature review and clinical case
title_sort	avapritinib: a new tyrosine kinase inhibitor for treatment of advanced gastrointestinal stromal tumors. the literature review and clinical case
publisher	IP Habib O.N.
publishDate	2021
url	https://doaj.org/article/6e46ed6345224af8a1b117b56a28b0d7
work_keys_str_mv	AT dariaafilonenko avapritinibanewtyrosinekinaseinhibitorfortreatmentofadvancedgastrointestinalstromaltumorstheliteraturereviewandclinicalcase AT belammedvedeva avapritinibanewtyrosinekinaseinhibitorfortreatmentofadvancedgastrointestinalstromaltumorstheliteraturereviewandclinicalcase AT andreyameshcheryakov avapritinibanewtyrosinekinaseinhibitorfortreatmentofadvancedgastrointestinalstromaltumorstheliteraturereviewandclinicalcase
_version_	1718406385340776448

Avapritinib: a new tyrosine kinase inhibitor for treatment of advanced gastrointestinal stromal tumors. The literature review and clinical case

Ejemplares similares